

Response to reviewer

Reviewer #1:

Specific Comments to Authors:

The authors comprehensively commented on the recent case reports of blastic plasmacytoid dendritic cell neoplasm to be published in the journal. They also summarized shortly pathogenesis, diagnosis and treatment of this rare disease, including the progress of molecular targeted therapy. The paper was well written. In page 2, lines 7-8 and 23, "Blastic Plasmacytoid Dendritic Cell Neoplasm" should be rewritten to "blastic plasmacytoid dendritic cell neoplasm".

Response:

Dear Reviewer #1,

Thank you for your insightful comments and positive evaluation of our manuscript. We are pleased to hear that you appreciate the comprehensiveness of our review and the quality of writing.

In accordance with your suggestion, we have revised the manuscript to ensure that the term "Blastic Plasmacytoid Dendritic Cell Neoplasm" is now consistently presented in lowercase as "blastic plasmacytoid dendritic cell neoplasm" throughout the text, specifically on page 2, lines 7-8 and 23.

We appreciate your attention to detail and your recommendations which have undoubtedly enhanced the clarity and quality of our paper.